An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

T. E. Witzig, Julie Marie Vose, P. L. Zinzani, C. B. Reeder, R. Buckstein, J. A. Polikoff, R. Bouabdallah, C. Haioun, H. Tilly, P. Guo, D. Pietronigro, A. L. Ervin-Haynes, M. S. Czuczman

Research output: Contribution to journalArticle

271 Citations (Scopus)

Abstract

Background: Lenalidomide is an immunomodulatory agent with antitumor activity in B-cell malignancies. This phase II trial aimed to demonstrate the safety and efficacy of lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular grade 3 lymphoma (FL-III), or transformed lymphoma (TL). Methods: Patients received oral lenalidomide 25 mg on days 1-21 every 28 days as tolerated or until progression. The primary end point was overall response rate (ORR). Results: Two hundred and seventeen patients enrolled and received lenalidomide. The ORR was 35% (77/217), with 13% (29/217) complete remission (CR), 22% (48/217) partial remission, and 21% (45/217) with stable disease. The ORR for DLBCL was 28% (30/108), 42% (24/57) for MCL, 42% (8/19) for FL-III, and 45% (15/33) for TL. Median progression-free survival for all 217 patients was 3.7 months [95% confidence interval (CI) 2.7-5.1]. For 77 responders, the median response duration lasted 10.6 months (95% CI 7.0-NR). Median response duration was not reached in 29 patients who achieved a CR and in responding patients with FL-III or MCL. The most common adverse event was myelosuppression with grade 4 neutropenia and thrombocytopenia in 17% and 6%, respectively. Conclusion: Lenalidomide is well tolerated and produces durable responses in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

Original languageEnglish (US)
Pages (from-to)1622-1627
Number of pages6
JournalAnnals of Oncology
Volume22
Issue number7
DOIs
StatePublished - Jul 4 2011

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Mantle-Cell Lymphoma
Lymphoma
B-Lymphocytes
Confidence Intervals
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
lenalidomide
Neutropenia
Antineoplastic Agents
Disease-Free Survival
Safety
Neoplasms

Keywords

  • Large cell lymphoma
  • Lenalidomide
  • Mantle cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. / Witzig, T. E.; Vose, Julie Marie; Zinzani, P. L.; Reeder, C. B.; Buckstein, R.; Polikoff, J. A.; Bouabdallah, R.; Haioun, C.; Tilly, H.; Guo, P.; Pietronigro, D.; Ervin-Haynes, A. L.; Czuczman, M. S.

In: Annals of Oncology, Vol. 22, No. 7, 04.07.2011, p. 1622-1627.

Research output: Contribution to journalArticle

Witzig, TE, Vose, JM, Zinzani, PL, Reeder, CB, Buckstein, R, Polikoff, JA, Bouabdallah, R, Haioun, C, Tilly, H, Guo, P, Pietronigro, D, Ervin-Haynes, AL & Czuczman, MS 2011, 'An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma', Annals of Oncology, vol. 22, no. 7, pp. 1622-1627. https://doi.org/10.1093/annonc/mdq626
Witzig, T. E. ; Vose, Julie Marie ; Zinzani, P. L. ; Reeder, C. B. ; Buckstein, R. ; Polikoff, J. A. ; Bouabdallah, R. ; Haioun, C. ; Tilly, H. ; Guo, P. ; Pietronigro, D. ; Ervin-Haynes, A. L. ; Czuczman, M. S. / An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. In: Annals of Oncology. 2011 ; Vol. 22, No. 7. pp. 1622-1627.
@article{67e828b43c47475d9ac5cbcd4104f464,
title = "An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma",
abstract = "Background: Lenalidomide is an immunomodulatory agent with antitumor activity in B-cell malignancies. This phase II trial aimed to demonstrate the safety and efficacy of lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular grade 3 lymphoma (FL-III), or transformed lymphoma (TL). Methods: Patients received oral lenalidomide 25 mg on days 1-21 every 28 days as tolerated or until progression. The primary end point was overall response rate (ORR). Results: Two hundred and seventeen patients enrolled and received lenalidomide. The ORR was 35{\%} (77/217), with 13{\%} (29/217) complete remission (CR), 22{\%} (48/217) partial remission, and 21{\%} (45/217) with stable disease. The ORR for DLBCL was 28{\%} (30/108), 42{\%} (24/57) for MCL, 42{\%} (8/19) for FL-III, and 45{\%} (15/33) for TL. Median progression-free survival for all 217 patients was 3.7 months [95{\%} confidence interval (CI) 2.7-5.1]. For 77 responders, the median response duration lasted 10.6 months (95{\%} CI 7.0-NR). Median response duration was not reached in 29 patients who achieved a CR and in responding patients with FL-III or MCL. The most common adverse event was myelosuppression with grade 4 neutropenia and thrombocytopenia in 17{\%} and 6{\%}, respectively. Conclusion: Lenalidomide is well tolerated and produces durable responses in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.",
keywords = "Large cell lymphoma, Lenalidomide, Mantle cell lymphoma",
author = "Witzig, {T. E.} and Vose, {Julie Marie} and Zinzani, {P. L.} and Reeder, {C. B.} and R. Buckstein and Polikoff, {J. A.} and R. Bouabdallah and C. Haioun and H. Tilly and P. Guo and D. Pietronigro and Ervin-Haynes, {A. L.} and Czuczman, {M. S.}",
year = "2011",
month = "7",
day = "4",
doi = "10.1093/annonc/mdq626",
language = "English (US)",
volume = "22",
pages = "1622--1627",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

AU - Witzig, T. E.

AU - Vose, Julie Marie

AU - Zinzani, P. L.

AU - Reeder, C. B.

AU - Buckstein, R.

AU - Polikoff, J. A.

AU - Bouabdallah, R.

AU - Haioun, C.

AU - Tilly, H.

AU - Guo, P.

AU - Pietronigro, D.

AU - Ervin-Haynes, A. L.

AU - Czuczman, M. S.

PY - 2011/7/4

Y1 - 2011/7/4

N2 - Background: Lenalidomide is an immunomodulatory agent with antitumor activity in B-cell malignancies. This phase II trial aimed to demonstrate the safety and efficacy of lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular grade 3 lymphoma (FL-III), or transformed lymphoma (TL). Methods: Patients received oral lenalidomide 25 mg on days 1-21 every 28 days as tolerated or until progression. The primary end point was overall response rate (ORR). Results: Two hundred and seventeen patients enrolled and received lenalidomide. The ORR was 35% (77/217), with 13% (29/217) complete remission (CR), 22% (48/217) partial remission, and 21% (45/217) with stable disease. The ORR for DLBCL was 28% (30/108), 42% (24/57) for MCL, 42% (8/19) for FL-III, and 45% (15/33) for TL. Median progression-free survival for all 217 patients was 3.7 months [95% confidence interval (CI) 2.7-5.1]. For 77 responders, the median response duration lasted 10.6 months (95% CI 7.0-NR). Median response duration was not reached in 29 patients who achieved a CR and in responding patients with FL-III or MCL. The most common adverse event was myelosuppression with grade 4 neutropenia and thrombocytopenia in 17% and 6%, respectively. Conclusion: Lenalidomide is well tolerated and produces durable responses in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

AB - Background: Lenalidomide is an immunomodulatory agent with antitumor activity in B-cell malignancies. This phase II trial aimed to demonstrate the safety and efficacy of lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular grade 3 lymphoma (FL-III), or transformed lymphoma (TL). Methods: Patients received oral lenalidomide 25 mg on days 1-21 every 28 days as tolerated or until progression. The primary end point was overall response rate (ORR). Results: Two hundred and seventeen patients enrolled and received lenalidomide. The ORR was 35% (77/217), with 13% (29/217) complete remission (CR), 22% (48/217) partial remission, and 21% (45/217) with stable disease. The ORR for DLBCL was 28% (30/108), 42% (24/57) for MCL, 42% (8/19) for FL-III, and 45% (15/33) for TL. Median progression-free survival for all 217 patients was 3.7 months [95% confidence interval (CI) 2.7-5.1]. For 77 responders, the median response duration lasted 10.6 months (95% CI 7.0-NR). Median response duration was not reached in 29 patients who achieved a CR and in responding patients with FL-III or MCL. The most common adverse event was myelosuppression with grade 4 neutropenia and thrombocytopenia in 17% and 6%, respectively. Conclusion: Lenalidomide is well tolerated and produces durable responses in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

KW - Large cell lymphoma

KW - Lenalidomide

KW - Mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=79959722615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959722615&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq626

DO - 10.1093/annonc/mdq626

M3 - Article

C2 - 21228334

AN - SCOPUS:79959722615

VL - 22

SP - 1622

EP - 1627

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -